Celebrating Pride Month at EMMA International

by | Jun 7, 2021 | Healthcare, MedTech, Pharmaceuticals, Quality

June 1 started the celebration of Pride Month, which commemorates Lesbian, Gay, Bisexual, and Transgender members. Celebrating Pride Month is also more than celebrating members of the LGBTQIA+, this month is also about recognizing that diversity fuels innovation and collaboration among a variety of industries, including the life sciences.

This month, there are several biopharmaceutical organizations that are taking initiative and celebrating the differences among their employees. For example, Eli Lily implemented a mentoring program that pairs their senior leadership team with employees that are a part of the LGBTQIA+ community. Eli Lilly mentions that they want to help educate employees about a variety of LGBTQIA+ topics within the workforce. The organization also hopes that this will help promote a sense of partnership and collaboration among its employees.

Another organization that is celebrating Pride Month is Pfizer, which is one of the leading organizations for inclusion and equality for LGBTQIA+ members. Pfizer launched an employee resource group that emphasizes their company values, like partnership, scientific innovation, and public health impact. Pfizer has also recently partnered with SAGE to bring awareness and support to the health care challenges that LGBTQIA+ individuals.

Additional organizations that are taking the initiative and celebrating diversity and inclusion in the biopharmaceutical industry include Astellas, Biogen, PhRMA, and Gilead.

EMMA International is proud to celebrate our LGBTQIA+ colleagues and clients and their contributions to the biopharmaceutical industry. If you need help with any quality, regulatory, or compliance aspect of your product, EMMA International’s team of experts has you covered. Contact us at 248-987-4497, or email info@emmainternational.com today!

1Powaleny, A. (2020). Celebrating PRIDE in biopharmaceutical science. Phrma.org. https://catalyst.phrma.org/celebrating-pride-in-biopharmaceutical-science

Abby McVay

Abby McVay

Research Analyst- Ms. McVay is EMMA International’s Research Analyst. She has experience in technical writing and clinical trials in many life science industries. She has experience with many different elements of quality and regulatory compliance. Ms. McVay holds a Bachelor of Science in Psychology from Manchester University as well as a Master of Science in Industrial and Organizational Psychology from Angelo State University.

More Resources

De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.
Is your product a medical device?

Is your product a medical device?

Many marketed products are classified as medical devices and you would not even know it. Medical devices range from latex gloves and tongue depressors to respirators and heart valves. To determine if the product is considered a medical device by the Food and Drug Administration (FDA) you will need to analyze if your product meets the definition of a medical device per the Food, Drug, and Cosmetic Act1.

Ready to learn more about working with us?

Pin It on Pinterest

Share This